TITLE

CLINIC ROUNDUP

PUB. DATE
March 2008
SOURCE
BioWorld Today;3/27/2008, Vol. 19 Issue 60, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs related to the biotechnology industry. Metabolex Inc. announced that it has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential treatment for Type II diabetes. Nventa Biopharmaceuticals Corp. revealed interim immunological data from the first two cohorts of its ongoing Phase I clinical trial of its product, HspE7, in patients with cervical intraepithelial neoplasia. A study was initiated by SemBioSys Genetics Inc. to demonstrate the safety of its safflower-produced insulin.
ACCESSION #
31486836

 

Related Articles

  • SEMBIOSYS GETS ALBERTA AWARD FOR PLANT BIOTECHNOLOGY.  // Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p6 

    Reports on the Alberta Science and Technology Award for Innovation in Industrial Research Prize received by biotechnology company SemBioSys Genetics Inc. for its contributions to plant biotechnology.

  • U.S. PATENT DISCLOSURES.  // BioWorld Today;10/31/2007, Vol. 18 Issue 212, p6 

    This section offers news briefs on U.S. patents awarded to the biotechnology industry. Nventa Biopharmaceuticals Corp. received a patent that covers compositions and methods for inducing or enhancing immune responses to a human papillomavirus antigen. Penwest Pharmaceuticals Co. obtained a...

  • Cervical Cancer Update.  // PharmaWatch: Cancer;Oct2007, Vol. 6 Issue 10, p8 

    The article reports that Nventa Biopharmaceuticals Corp. has started a Phase I trial which evaluates the safeness and tolerability of its therapeutic vaccine in patients with cervical intraepithelial neoplasia (CIN) in the U.S. It also aims to assess T-cell and B-cell specific HPV-E7 immune...

  • Nventa reports positive results from Phase I cervical dysplasia trial.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p11 

    The article reports on the result of the drug study conducted by Nventa Biopharmaceuticals Corp. which assesses the effectiveness of its HspE7 drug for treating cervical intraepithelial neoplasia (CIN) patients. The study focused on evaluating the drug's response and immunogenecity to different...

  • Research Update.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p4 

    The article offers news briefs related to medical research. Sinovac Biotech Ltd. started its move to immunize volunteers for pandemic avian influenza vaccine trial. Thallion Pharmaceuticals Inc. has completed its clinical trial with ECO-4601 as part of the phase II extention for cancer drug...

  • NVENTA UNVEILS IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 TRIAL.  // Worldwide Biotech;May2008, Vol. 20 Issue 5, p1 

    The article reports on the release of interim immunological data from the first two cohorts of Nventa Biopharmaceuticals Corporation's ongoing Phase 1 clinical trial of its lead product candidate, HspE7. The product is being tested in patients with cervical intraepithelial neoplasia (CIN). It...

  • A bean counter's take on human resources. Watson, Paul // Nature Biotechnology;Jun2004, Vol. 22 Issue 6, p783 

    SemBioSys Genetics Inc. of Calgary, Alberta, Canada is pushing the frontiers of what is possible in biotechnology by fundamentally changing the way proteins are made. The large investments made in immunology, genomics, high-throughput molecular screening and other technologies in the 1990s are...

  • SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI.  // BioPharm International;Jul2008, Vol. 21 Issue 7, p14 

    The article reports on the demonstration of SemBioSys Genetics Inc. concerning the function of its safflower-produced Apo AI. It states that Apo AI increased the cholesterol mobilization in mice, in conjunction with analytical and in vitro assays. It also cites that in human trials,...

  • Company Strategy.  // PharmaWatch: Biotechnology;May2009, Vol. 8 Issue 5, p18 

    The article offers world news briefs related to company strategy of biotechnology industry. An arrangement agreement was signed by Akela Pharma Inc. and Nventa Biopharmaceuticals Corp. to combine the two companies. The $16 per share offer made by Astellas Pharma Inc. for CV Therapeutics Inc....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics